Pharma BD Deal Intelligence
Novartis paid $1.5B to become #1 in generic dermatology, then spent the next decade trying to sell it for less, getting caught in a price-fixing scandal, and finally giving the whole business away in the 2023 Sandoz spinoff.
Full analysis, sources & comparables →Sandoz to acquire Fougera for $1.525B all-cash; Fougera 2011 net sales of $429M and EBITDA of $173M imply an 8.8x EBITDA multiple; combined entity becomes…
Acquisition expected to position Sandoz as global #1 in generic dermatology with ~$620M combined annual sales; deal leverages Fougera's semi-solid formulation…
Sandoz closed the Fougera deal in July 2012, locking in #1 generic dermatology position; FTC consent required divestiture of four topical products to preserve…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Sandoz (Novartis division) acquired Fougera Pharmaceuticals for $1.525B all-cash. Made Sandoz #1 in generic dermatology globally and in the US. Fougera 2011 net sales $429M. FTC required divestiture of 4 topical products. Sellers: Nordic Capital, DLJ Merchant Banking, Avista.
Novartis paid $1.5B to become #1 in generic dermatology, then spent the next decade trying to sell it for less, getting caught in a price-fixing scandal, and finally giving the whole business away in the 2023 Sandoz spinoff.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Fougera Pharmaceuticals Inc. (this deal) | 2012 | $1.5B | 34 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2012 deals · Novartis AG deals · Dermatology deals